Bristol-Myers Squibb raises forecast as strong 2nd-qtr 2011 results beat forecasts

29 July 2011

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported second-quarter 2011 net profit of $902 million, or $0.52 a share, down nearly 3% due to higher taxes and increased costs for production, marketing and administration. Adjusted (non-GAPP) earnings were $971 million, or $0.56 a share. However, net sales for the quarter at $5.4 billion, increase 14%, or 10% excluding the impact of foreign exchange, compared to the same period a year ago.

The company still beat expectations; analysts surveyed by FactSet Research expected earnings of $0.55 cents a share, on revenue of $5.05 billion. B-MS is raising its 2011 GAAP EPS guidance range to $2.08 to $2.18 and its non-GAAP EPS range to $2.20 to $2.30.

US net sales increased 15% to $3.6 billion, while international net sales increased 13%, or 3% excluding foreign exchange impact, to $1.9 billion. The incremental impact in 2011 over 2010 of the two additional US health care reform provisions for new discounts associated with the Medicare Part D coverage gap and the annual pharmaceutical company fee decreased second quarter EPS by approximately $0.03, the New York-based firm noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical